ACCO

Thank you for attending an ACCO workshop.

Your assistance completing this form is appreciated. It also ensures maximum RACGP / ACRRM points for the activity.

Post test

First name*

Last name*

Street Address

Town/Suburb*

Postcode

State/Territory/Country*

Country*

Practice type*

Where was your workshop held?

What has changed to your practice since attending this workshop?*

To what extent has this workshop improved your skills in managing skin cancer:

Enormously

Considerably

Slightly

Marginally

Not at all

Q1. Types of BCC do not include

Superficial

Infiltrating

Spitzoid

Micronodular

Q2. Basal cell carcinomas

Frequently metastasize

Never metastasize

Rarely metastasize

Only metastasize on face

Q3. The minimum excision margin for a melanoma Breslow thickness 0.8 mm and no ulceration is?

5mm

10mm

20mm

30mm

Q4. Drugs that have proven value in managing melanoma do not include:

Pembrolizumab

Dabrafenib

Vismodegib

Trametinib

Q5. Risk factors for metastases in primary SCC do not include:

Thick tumour > 5mm depth

Location on the eyelid

Poorly differentiated

Hyperkeratotic surface

Q6. You can treat morphoeic BCC by:

Topical imiquimod

Surgical Excision

Curette and diathermy

All of the above

Q7. Independent poor prognostic factors for melanoma do not include:

Clark Level

Breslow thickness

Trunk location

Ulceration

Q8. Infraorbital distribution does not include:

Medial zygomatic arch

Lower eyelid

Upper lip

Medial cheek

Q9. Photodynamic therapy does not:

Cause pain and redness

Require light source

Need topical agent applied

Reduce skin cancer risk

Q10. Sentinel node biopsy for melanoma

Increases 5 year survival

Has morbidity around 4%

Provides prognostic info

Can't be done post excision

Q11. Lentigo maligna is:

A benign lesion

A type of BCC

A type of SCC

A type of melanoma

Q12. Atypical fibroxanthoma is a:

Type of dermatofibroma

Type of poor scar reaction

Low grade malignancy

Subcutaneous lesion

Q13. Topical agents approved for actinic keratoses do not include:

Imiquimod

Ingenol mebutate

Ibuprofen

5 fluro uracil

Q14. Curettage and electrodessication can be used to manage:

Superficial BCC

Melanoma in situ

Well differentiated SCC

Eccrine adenocarcinoma

Q15. Acral melanoma does not occur

In the germinal nail matrix

Behind the calcaneus

On the helix of the ear

On hypothenar eminence

Q16. Margin control surgery is ideal for:

Infiltrating BCC on nose

Superficial BCC on neck

Bowens disease on toe

Dermatofibroma

Q17. Skin infections do not include:

Impetigo

Pyogenic granuloma

Veruuca vulgaris

Molluscum contagiosum

Q18. Which has the most similar clinical appearance to a nodular BCC:

Sebaceous hyperplasia

Lentigo maligna

Well differentiated SCC

Verruca vulgaris

Q19. Curette and cryotherapy can be used to manage:

Melanoma in situ

Guttate Psoriasis

Morphoeic BCC

SCC in situ

Q20. Nivolumab is a:

BRAF inhibitor

MEK inhibitor

Immune suppressant

Program cell death agent

How was this workshop relevant to your practice?

Reflecting on this workshop, what do you see as further gaps in your knowledge to improve upon?

The BEST thing about this ACCO workshop *

The WORST thing about this ACCO workshop *

Your advice to improve this event?

Would you recommend this workshop to others? Why?

EVALUATION

Post test

1101/5 Caravel Ln, Docklands VIC 3008, Australia

admin@acco.edu.au

Workshops

Useful Links

Certifications